MDWD MediWound

MediWound to Report Second Quarter 2025 Financial Results

MediWound to Report Second Quarter 2025 Financial Results

MediWound to Report Second Quarter 2025 Financial Results

Conference call and webcast scheduled for Thursday, August 14 at 8:30 a.m. Eastern Time

YAVNE, Israel, August 4, 2025 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will release its financial results for the second quarter ended June 30, 2025 on Thursday, August 14, 2025.

Following the release, MediWound’s management will host a conference call and live webcast at 8:30 a.m. Eastern Time to discuss these financial results and provide corporate updates.

Dial-in and call details are as follows:

Conference Call & Webcast Details

Toll-Free:                1-844-676-8833

Israel:                      1-80-9212373

International:         1-412-634-6869

Webcast:                

To access the call, participants should dial the applicable telephone number above at least 5 minutes prior to the start of the call. An archived version of the webcast will be available for replay on the Investors section of the MediWound website.

About MediWound

MediWound Ltd. (Nasdaq: MDWD) is a global biotechnology company focused on developing and commercializing enzymatic therapies for non-surgical tissue repair. The company’s FDA-approved biologic, NexoBrid®, is indicated for the enzymatic removal of eschar in thermal burns and is marketed in the U.S., European Union, Japan, and other international markets. MediWound is also advancing EscharEx®, a late-stage investigational therapy for the debridement of chronic wounds. EscharEx has demonstrated clinical advantages over the leading enzymatic debridement product and targets a substantial global market opportunity.

For more information visit and follow us on .

MediWound Contacts:                                                        

Hani Luxenburg                                                Daniel Ferry

Chief Financial Officer                                     Managing Director

MediWound Ltd.                                               LifeSci Advisors, LLC

                                                 

Media Contact: 

Ellie Hanson

FINN Partners for MediWound



EN
04/08/2025

Underlying

MDWDMediWound

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MediWound

Free Trial
MDWD MEDIWOUND

MediWound Ltd: 1 director

A director at MediWound Ltd bought 11,200 shares at 17.740USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...

12h / 51m 12h / 51m 1 EN
 PRESS RELEASE
Free
MDWD MEDIWOUND

MediWound to Present at the H.C. Wainwright 27th Annual Global Investm...

MediWound to Present at the H.C. Wainwright 27th Annual Global Investment Conference YAVNE, Israel, August 20, 2025 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Ofer Gonen, Chief Executive Officer, will participate in a fireside chat, hosted by Swayampakula Ramakanth, Managing Director, Senior Equity Research Analyst, on Monday, September 8, 2025 at 4:30p.m. ET at the H.C. Wainwright 27th Annual Global Investment Conference. A live webcast of the event will be accessible both and on MediWound’s website,...

13h / 45m 1 EN
 PRESS RELEASE
Free
MDWD MEDIWOUND

MediWound Reports Second Quarter 2025 Financial Results and Provides C...

MediWound Reports Second Quarter 2025 Financial Results and Provides Corporate Update VALUE Phase III Trial of EscharEx® in Venous Leg Ulcers Continues to Enroll Patients NexoBrid® Manufacturing Expansion on Track; Full Operational Capacity Expected by Year-End 2025 Additional Strategic Research Collaborations Established with Essity and Convatec Second Quarter 2025 Revenue of $5.7 Million, Up 43% from Prior Quarter Conference Call Today, August 14, 2025, at 8:30am Eastern Time YAVNE, Israel, Aug. 14, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-ge...

August 14, 2025 1 EN
 PRESS RELEASE
Free
MDWD MEDIWOUND

MediWound Announces New EscharEx® Phase II Data Demonstrating Strong L...

MediWound Announces New EscharEx® Phase II Data Demonstrating Strong Link Between Wound Bed Preparation and Wound Closure in Venous Leg Ulcers MediWound Announces New EscharEx® Phase II Data Demonstrating Strong Link Between Wound Bed Preparation and Wound Closure in Venous Leg Ulcers Post hoc analysis published in Advances in Wound Care, provides clinical evidence supporting wound bed preparation as a critical step in the healing process YAVNE, Israel, August 13, 2025 (GLOBE NEWSWIRE) – MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue re...

August 13, 2025 1 EN
 PRESS RELEASE
Free
MDWD MEDIWOUND

MediWound to Report Second Quarter 2025 Financial Results

MediWound to Report Second Quarter 2025 Financial Results MediWound to Report Second Quarter 2025 Financial Results Conference call and webcast scheduled for Thursday, August 14 at 8:30 a.m. Eastern Time YAVNE, Israel, August 4, 2025 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will release its financial results for the second quarter ended June 30, 2025 on Thursday, August 14, 2025. Following the release, MediWound’s management will host a conference call and live webcast at 8:30 a.m. Eastern Time...

August 4, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch